Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mezigdomide by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Mezigdomide is under clinical development by Bristol-Myers Squibb and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData,...
Mezigdomide by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval
Mezigdomide is under clinical development by Bristol-Myers Squibb and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Mezigdomide?
Mezigdomide is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Refractory Multiple Myeloma. According...